149 related articles for article (PubMed ID: 2292349)
1. Postprandial glycemic control, hormonal effects and carbohydrate malabsorption during long-term administration of the alpha-glucosidase inhibitor miglitol.
Lembcke B; Diederich M; Fölsch UR; Creutzfeldt W
Digestion; 1990; 47(1):47-55. PubMed ID: 2292349
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man.
Lembcke B; Fölsch UR; Gatzemeier W; Ebert R; Siegel E; Creutzfeldt W
Pharmacology; 1991; 43(6):318-28. PubMed ID: 1784628
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of sucrose- and starch-induced glycaemic and hormonal responses by the alpha-glucosidase inhibitor emiglitate (BAY o 1248) in healthy volunteers.
Lembcke B; Fölsch UR; Gatzemeier W; Lücke B; Ebert R; Siegel E; Creutzfeldt W
Eur J Clin Pharmacol; 1991; 41(6):561-7. PubMed ID: 1815967
[TBL] [Abstract][Full Text] [Related]
4. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
[TBL] [Abstract][Full Text] [Related]
5. alpha-Glucosidase inhibition by miglitol in NIDDM patients.
Kingma PJ; Menheere PP; Sels JP; Nieuwenhuijzen Kruseman AC
Diabetes Care; 1992 Apr; 15(4):478-83. PubMed ID: 1499461
[TBL] [Abstract][Full Text] [Related]
6. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
[TBL] [Abstract][Full Text] [Related]
7. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.
Sels JP; Nauta JJ; Menheere PP; Wolffenbuttel BH; Nieuwenhuijzen Kruseman AC
Br J Clin Pharmacol; 1996 Oct; 42(4):503-6. PubMed ID: 8904624
[TBL] [Abstract][Full Text] [Related]
8. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
[TBL] [Abstract][Full Text] [Related]
9. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase.
Joubert PH; Foukaridis GN; Bopape ML
Eur J Clin Pharmacol; 1987; 31(6):723-4. PubMed ID: 3549325
[TBL] [Abstract][Full Text] [Related]
10. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Heinz G; Komjati M; Korn A; Waldhäusl W
Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
[TBL] [Abstract][Full Text] [Related]
12. Effects of alpha-glucosidase inhibitors on mouth to caecum transit time in humans.
Ladas SD; Frydas A; Papadopoulos A; Raptis SA
Gut; 1992 Sep; 33(9):1246-8. PubMed ID: 1427379
[TBL] [Abstract][Full Text] [Related]
13. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
[TBL] [Abstract][Full Text] [Related]
15. Intestinal and metabolic responses to an alpha-glucosidase inhibitor in normal volunteers.
Holt PR; Thea D; Yang MY; Kotler DP
Metabolism; 1988 Dec; 37(12):1163-70. PubMed ID: 3057329
[TBL] [Abstract][Full Text] [Related]
16. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
[TBL] [Abstract][Full Text] [Related]
17. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD
Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the absorption of dietary carbohydrate in man by two new glycosidase inhibitors.
Taylor RH; Barker HM; Bowey EA; Canfield JE
Gut; 1986 Dec; 27(12):1471-8. PubMed ID: 3804023
[TBL] [Abstract][Full Text] [Related]
19. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?
Joubert PH; Venter HL; Foukaridis GN
Br J Clin Pharmacol; 1990 Sep; 30(3):391-6. PubMed ID: 2223417
[TBL] [Abstract][Full Text] [Related]
20. Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.
Samad AH; Ty Willing TS; Alberti KG; Taylor R
Diabetes Care; 1988 Apr; 11(4):337-44. PubMed ID: 3042310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]